• If you are wondering whether Cencora's current share price lines up with its underlying worth, it helps to look past the headline numbers and focus on what the valuation signals are really saying.
• The stock closed at US$305.90, with returns of a 2.0% decline over the last week, a 5.8% decline over the last month, a 9.7% decline year to date, a 5.9% gain over one year, 86.7% over three years and 168.5% over five years. This gives you a mix of recent weakness and longer term strength to think about.
• Recent coverage has focused on Cencora's role in the healthcare supply chain and how investors are reassessing valuations across the sector, which provides some context for the recent pullback. Sector wide sentiment, regulatory discussions and changing expectations about growth in healthcare services are all key pieces of the puzzle when you look at these moves.
• On Simply Wall St's valuation model, Cencora scores 3 out of 6 checks for being undervalued. The next sections will compare different valuation approaches and, finally, introduce a way to interpret valuation that goes beyond any single metric.

Approach 1: Cencora Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It focuses on the cash that could be available to shareholders rather than accounting profits.

For Cencora, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is about $3.69b. Analyst forecasts and subsequent extrapolations indicate projected free cash flow of about $4.85b by 2030, with a series of annual projections in between, such as $2.99b in 2026 and $3.66b in 2027. Beyond the explicit analyst horizon, Simply Wall St extends the trend using its own estimates to build a full 10 year path.

When all of these projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $606.79 per share. Compared with the recent share price of $305.90, this suggests the stock is about 49.6% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 49.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Cencora Price vs Earnings

For a profitable company like Cencora, the P/E ratio is a useful way to relate what you pay for the stock to the earnings it generates. It helps you see how many dollars investors are currently willing to pay for each dollar of earnings.

What counts as a "normal" P/E really depends on two things: how quickly earnings are expected to grow and how risky those earnings are perceived to be. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually calls for a lower P/E.

Cencora currently trades on a P/E of 36.61x, compared with the Healthcare industry average of 24.86x and a peer average of 21.33x. Simply Wall St also calculates a Fair Ratio of 29.72x, which is its proprietary estimate of an appropriate P/E based on factors such as earnings growth, industry, profit margins, market cap and key risks.

The Fair Ratio aims to be more tailored than a simple comparison with peers or the broad industry because it brings those company specific drivers into one number. With Cencora’s current P/E above the Fair Ratio, the stock screens as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Cencora Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as your way to attach a clear story about Cencora. For example, you might consider whether digital investments and specialty drug demand support higher revenue, earnings and margins, or whether margin pressure, regulatory scrutiny and competition keep those in check. You can link that story to a forecast and a fair value inside Simply Wall St’s Community page, and then see what that fair value implies against today’s price. Different investors can build very different views, from a more optimistic narrative that lines up with a fair value around the top analyst target of US$447 to a more cautious one closer to US$340. All of these Narratives can automatically refresh as new earnings, news or guidance are added.

Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.